Cori Clinical Raises $4M for Trial-Design AI
Cori Clinical has raised $4M to use AI to improve clinical-trial design, regulatory preparation and operational planning.
AI drug discovery gets most of the attention, but many promising medicines still lose time and money once they enter clinical development.
What happened
London-based Cori Clinical raised a $4 million seed round to develop its AI workspace for clinical-trial teams. The platform combines internal company knowledge with regulatory guidance, trial registries and external datasets to support protocol design, submission packages and operational planning.
The goal is to help teams make better trial decisions earlier and reduce the fragmented manual work involved in moving from a drug candidate to a human study.
Why it matters
Clinical trials are expensive, slow and vulnerable to design mistakes. Poor protocol choices can create recruitment problems, amendments and delays that materially increase development costs.
A system that brings relevant evidence and regulatory context into one workflow could improve planning even without replacing scientific or clinical judgement.
The opportunity is particularly large because AI adoption in life sciences is expanding downstream. The first wave focused heavily on molecule discovery; newer companies are targeting the operational layers that determine whether those molecules can actually reach patients.
The bigger picture
The most valuable AI tools in biotech may not always be the ones inventing drugs. There is also a large market for software that improves the development process around them.
Cori Clinical represents that shift toward AI infrastructure for clinical execution, where better decisions and fewer delays can have direct economic value.